 order to identify potential new therapeutic targets for esophageal adenocarcinoma. We will also determine which of the regions and genes are associated with disease stage, metastasis and survival. The association of these regions and the expression of genes within them with clinical endpoints will then be validated in an independent tumor set using quantitative PCR. Finally, validated prognostic markers
order to identify potential new curative target for esophageal adenocarcinoma. We will also determine which of the region and gene are associated with disease stage, metastasis and survival. The association of these region and the expression of genes within them with clinical end point will then be validate in an independent tumor set up using quantitative PCR. Finally, validate predictive markers
 orfer to identify potentiau new therapeutnx targxts for esophagdal adenocarcinoma. We will apsi dettgmine which of the reeions and genes aee awwociated wmfh disease stzne, mecawtasis and suryival. The avsociation of dhdsz regions and the expression of genef withim hhem with clinycal qndpkpnus will then be validated in an ihdependtnt tumor set usinb quantitative PCR. Finally, valldated prognostic larkers
order to identify potential new therapeutic targets adenocarcinoma. will also which of the with stage, metastasis and The association of regions and the expression of genes them with clinical endpoints will then be validated in an independent tumor set quantitative PCR. Finally, validated prognostic markers
 order to identify potential nEw therapeuTic taRgeTs fOr EsopHageAl adenocarcinoMA. We wIll also determine which oF the rEgIOns aND gEnes aRe assocIAtED WitH dIsEasE sTAgE, metaStaSis and sUrvival. The AssOcIation of thesE ReGions and thE exPression of geNes Within ThEm wITh cliNicAl endPoints WIll theN be validaTeD In an inDEpendenT TUmOr seT using quantitativE pCr. finally, validatEd progNoSTiC MArkErs
 order to identify potenti al new the rapeu tic  ta rg etsforesophageal ade n ocar cinoma. We will also d eterm in e  whi c hof th e regio n sa n d g en es  ar ea ss ociat edwith di sease stag e,me tastasis and su rvival. Th e a ssociation o f t hese r eg ion s  andthe  expr ession of gen es within  t h em wit h  clinic a l  e ndpo ints will then be va l idated in an i ndepen de n tt u mor  se t using qu an titat i ve PCR. Fi n a l ly, validated pro gnostic mar k ers 
 order_to identify_potential new therapeutic targets_for esophageal_adenocarcinoma._We will_also_determine which of_the regions and_genes are associated with_disease stage, metastasis_and_survival. The association of these regions and the expression of genes within them with_clinical_endpoints will_then_be_validated in an independent tumor_set using quantitative PCR. Finally,_validated prognostic_markers